GlassScriptPhysician profile
Sean Stehr
NPI 1245433234
$4,878.51
in general payments reported to CMS, 2019-2025
24 companies · $681 in 2025
The $681 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $427 · 2021: $1,176 · 2022: $827 · 2023: $404 · 2024: $767 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,137.99 | 2021-2025 | Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $700.64 | 2019-2025 | Ajovy |
| Amgen INC. | $424.64 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.74 | 2020-2025 | Relistor |
| Valinor Pharma, LLC | $386.07 | 2023-2025 | Movantik |
| Lilly USA, LLC | $204.67 | 2019-2023 | Emgality |
| Horizon Therapeutics Plc | $198.42 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $195.21 | 2019-2025 | Belbuca |
| Arbor Pharmaceuticals, INC. | $184.24 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $176.52 | 2021 | |
| Pfizer INC. | $147.83 | 2019-2025 | |
| Stryker Corporation | $143.91 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.74 | 2022 | |
| Allergan, INC. | $83.81 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $83.51 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $82.23 | 2021 | |
| Assertio Therapeutics, INC. | $62.29 | 2019 | |
| Redhill Biopharma INC. | $50.75 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $18.84 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.73 | 2025 | |
| Zyla Life Sciences, INC. | $17.36 | 2019 | |
| Metacel Pharmaceuticals LLC | $16.21 | 2022 | |
| Shionogi INC | $15.78 | 2019 | |
| Daiichi Sankyo INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Stehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.